Tempest Therapeutics, Inc.
Clinical-stage oncology company developing small molecule and cell therapies for cancer.
TPST | US
Overview
Corporate Details
- ISIN(s):
- US69014Q1013 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2000 SIERRA POINT PARKWAY, 94005 BRISBANE
- Website:
- https://www.tempesttx.com/
Description
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tempest Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tempest Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tempest Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
